- 专利标题: Brain-targeting prodrug for AMPA receptor synergist, and pharmaceutical applications thereof
-
申请号: US16093754申请日: 2017-04-11
-
公开(公告)号: US10759822B2公开(公告)日: 2020-09-01
- 发明人: Song Li , Xinbo Zhou , Dian Xiao , Wu Zhong , Junhai Xiao , Zhibing Zheng , Xingzhou Li , Yunde Xie , Xiaokui Wang
- 申请人: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China
- 申请人地址: CN Beijing
- 专利权人: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China
- 当前专利权人: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China
- 当前专利权人地址: CN Beijing
- 代理机构: Sterne, Kessler, Goldstein & Fox P.L.L.C.
- 优先权: com.zzzhc.datahub.patent.etl.us.BibliographicData$PriorityClaim@466503c8
- 国际申请: PCT/CN2017/080083 WO 20170411
- 国际公布: WO2017/177896 WO 20171019
- 主分类号: C07H13/04
- IPC分类号: C07H13/04 ; C07D413/12 ; C07D271/12 ; A61P11/00 ; A61P25/28 ; C07H1/00 ; A61K31/7056 ; A61K31/4245
摘要:
Disclosed in the present invention is a compound of Formula (I), a geometric or optical isomer, a pharmaceutically acceptable salt, a solvate or a polymorph thereof. Also disclosed in the present invention is a composition comprising the compound of Formula (I), the geometric or optical isomer, the pharmaceutically acceptable salt, the solvate or the polymorph thereof. Also disclosed in the present invention is a use of the compound of Formula (I), the geometric or optical isomer, the pharmaceutically acceptable salt, the solvate or the polymorph thereof in the treatment of a disease or disorder such as a hypoglutamatergic condition, a neurodegenerative disease or respiratory depression, particularly in the treatment of a disease or disorder associated with AMPA receptor.
公开/授权文献
信息查询